Physician profile
Brighton M Patrick
NPI 1538698162
$5,320.24
in general payments reported to CMS, 2019-2025
59 companies · $985 in 2025
The $985 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $487 · 2022: $1,708 · 2023: $997 · 2024: $1,144 · 2025: $985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,013 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,013.44 |
| Education | $112.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $409.24 | 2021-2024 | Talvey, Tecvayli, Darzalex |
| Novartis Pharmaceuticals Corporation | $376.43 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $368.96 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $256.24 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Abbvie INC. | $241.22 | 2024-2025 | |
| Gilead Sciences, INC. | $232.55 | 2022-2025 | Trodelvy |
| Amgen INC. | $186.53 | 2021-2024 | Lumakras, Evenity, Prolia |
| Ipsen Biopharmaceuticals, INC | $171.65 | 2023-2025 | Onivyde |
| Regeneron Healthcare Solutions, INC. | $162.53 | 2021-2025 | Libtayo, Lynozyfic |
| Jazz Pharmaceuticals INC. | $148.25 | 2022-2023 | |
| Karyopharm Therapeutics INC. | $137.85 | 2022-2024 | Xpovio |
| Bayer Healthcare Pharmaceuticals INC. | $135.42 | 2022-2025 | |
| Pfizer INC. | $133.67 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $131.80 | 2022-2025 | Imfinzi |
| Glaxosmithkline, LLC. | $127.44 | 2021-2025 | Ojjaara, Zejula, Jemperli |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brighton Patrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.